The Agence Marocaine du Médicament et des Produits de Santé (AMMPS) has lifted suspensions on nine products from manufacturer Novopharma.
The regulatory decision, announced on 3 November 2026, follows a 22 July 2026 suspension of multiple marketing authorisations and one registration certificate for the pharmaceutical manufacturer. The AMMPS evaluated corrective and preventive measures implemented by Novopharma to address identified non-conformities and restore compliance with regulatory requirements.
The authority confirmed that Novopharma has complied with all identified non-conformities through implementation of required corrective and preventive actions. AMMPS services verified the relevance of these measures and their capacity to control the initially identified deviations.
The lifted suspensions cover eight pharmaceutical specialties and one health product:
- FLUSTAPH 125 mg/5 ml, 100 ml bottle, powder for oral suspension
- FLUSTAPH 250 mg/5 ml, 100 ml bottle, powder for oral suspension
- TORVA 10 mg, 30 film-coated tablets
- TORVA 20 mg, 30 film-coated tablets
- DISPAMOX 125 mg, 100 ml bottle, powder for oral suspension
- DISPAMOX 250 mg, 100 ml bottle, powder for oral suspension
- DISPAMOX 500 mg, 100 ml bottle, powder for oral suspension
- ROXAM 20 mg, 8 sachets
- AGIDERM 2% cream, 15 g tube
The health product ARTHRODONT Classic, 75 ml gingival paste, also has its suspension lifted.
The AMMPS did not specify the nature of the original non-conformities, the quantities of products affected by the suspension, distribution patterns, or whether any supply shortages occurred during the suspension period.
Source: Agence Marocaine du Médicament et des Produits de Santé (AMMPS), Information Note 03/11/2026, 3 November 2026: https://ammps.gov.ma/note-information/novopharma-levee-de-la-suspension-des-autorisations-de-mise-sur-le-marche-de-specialites-pharmaceutique-et-du-certificat-denregistrement-dun-produit-de-sante
